Soraprazan: Setting new standards in inhibition of gastric acid secretion

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 866-874

  Simon, W A ^a   Herrmann, Michael ^a   Klein, T ^a   Shin, J M ^b   Huber, R ^a   Senn Bilfinger, J ^a   Postius, S ^a  

^a ALTANA PHARMA AG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ESOMEPRAZOLE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; SORAPRAZAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING KINETICS; CONTROLLED STUDY; DOG; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH GLAND; STOMACH PH; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ULCER AGENTS; BENZAZEPINES; DOGS; ENZYME INHIBITORS; GASTRIC ACID; GASTRIC MUCOSA; GENE EXPRESSION; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; KINETICS; MALE; MOLECULAR STRUCTURE; NA(+)-K(+)-EXCHANGING ATPASE; NAPHTHYRIDINES; NIACINAMIDE; NIGERICIN; OMEPRAZOLE; POTASSIUM; RABBITS; STOMACH; SWINE;

EID: 34248593276     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120428     Document Type: Article

References (41)

1. Ang TL and Fock KM (2006) Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol 21 (Suppl 5):125-128.
2. Beil W, Hackbarth I, and Sewing KF (1986) Mechanism of gastric antisecretory effect of SCH 28080. Br J Pharmacol 88:19-23.
3. Bell NJ, Burget D, Howden CW, Wilkinson J, and Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 (Suppl 1):59-67.
4. Berglindh T, Helander HF, and Obrink KJ (1976) Effects of secretagogues on oxygen consumption, aminopyrine accumulation and morphology in isolated gastric glands. Acta Physiol Scand 97:401-414.
5. Berglindh T and Obrink KJ (1976) A method for preparing isolated glands from the rabbit gastric mucosa. Acta Physiol Scand 96:150-159.
6. Bytzer P and Blum AL (2004) Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 20:389-398.
7. DiPalma JA (2001) Management of severe gastroesophageal reflux disease. J Clin Gastroenterol 32:19-26.
8. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55: 170-171.
9. +-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochim Biophys Acta 307:169-180.
10. +-adenosine triphosphatase α subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 109:1134-1141.
11. Geering K (2001) The functional role of β subunits in oligomeric P-type ATPases. J Bioenerg Biomembr 33:425-438.
12. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, and Sturm E (1995) Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 9:363-378.
13. + accumulation in hog gastric membranes by trifluoperazine, verapamil and 8-(N,N-diethylamino)octyl-3,4,5- trimethoxybenzoate. Biochim Biophys Acta 770:65-72.
14. +)-ATPase. Biochem Pharmacol 37:2231-2236.
15. +)-ATPase. J Biol Chem 264:5545-5551.
16. Klinkenberg-Knoll EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, et al. (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118:661-669.
17. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
18. +-ATPase. J Biol Chem 265:5030-5036.
19. Postius S, Brauer U, and Kromer W (1991) The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog. Life Sci 49:1047-1052.
20. Rabon E, Chang H, and Sach G (1978) Quantitation of hydrogen ion and potential gradients in gastric plasma membrane vesicles. Biochemistry 17:3345-3353.
21. +-ATPase. Methods Enzymol 157:649-654.
22. Sachs G (2001) Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 13 (Suppl 1):35-41.
23. Sachs G (2003) Physiology of the parietal cell and therapeutic implications. Pharmacotherapy 23:68-73.
24. + pump in plasma membranes of hog stomach. J Biol Chem 251:7690-7698.
25. Sachs G, Shin JM, and Howden CW (2006) Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23 (Suppl 2):2-8.
26. Sachs G, Shin JM, Vagin O, Munson K, Weeks D, Scott DR, and Voland P (2002) Current trends in the treatment of upper gastrointestinal disease. Best Pract Res Clin Gastroenterol 16:835-849.
27. Schaltenbrand R, Huber R, Cotoraci CA, Mascher H, Potthast H, and Hole U (2001) Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule. Int J Clin Pharmacol Ther 39:453-459.
28. Senn-Bilfinger J, Ferguson JR, Holmes MA, Lumbard KW, Huber R, Zech K, Hummel RP, and Zimmermann PJ (2006) Glucuronide conjugates of soraprazane (BY359), a new potassium-competitive acid blocker (P-CAB) for treatment of acid-related diseases. Tetrahedron Lett 47:3321-3323.
29. +)-ATPase by proton pump inhibitors. J Am Chem Soc 126:7800-7811.
30. Shin JM, Grundler G, Senn-Bilfinger J, Simon WA, and Sachs G (2005) Functional consequences of the oligomeric form of the membrane-bound gastric H,K-ATPase. Biochemistry 44:16321-16332.
31. Shin JM and Sachs G (2002) Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 123:1588-1597.
32. + ATPase. J Biol Chem 256:2682-2690.
33. Stolte M, Vieth M, Schmitz JM, Alexandridis T, and Seifert E (2000) Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 35:1125-1130.
34. Teyssen S, Singer MV, Pfützer R, Heinze H, and Fischer R (2001) Reliable acid suppression with pantoprazole contrasts with rapid development of tolerance to ranitidine in healthy individuals. Clin Drug Investig 21:273-279.
35. + access to the ion binding domain. Biochemistry 41:12755-12762.
36. Vagin O, Munson K, Denevich S, and Sachs G (2003) Inhibition kinetics of the gastric H,K-ATPase by K-competitive inhibitor SCH28080 as a tool for investigating the luminal ion pathway. Ann NY Acad Sci 986:111-115.
37. Vagin O, Turdikulova S, Yakubov I, and Sachs G (2005) Use of the H,K-ATPase β subunit to identify multiple sorting pathways for plasma membrane delivery in polarized cells. J Biol Chem 280:14741-14754.
38. von Büdingen C, Boer R, Sachs G, and Simon WA (1996) Reversible binding of acid pump antagonist to the gastric H,K-ATPase. Gastroenterology 110:A287.
39. +-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem 262:2077-2084.
40. +-ATPase rich membranes isolated from resting or stimulated rabbit fundic mucosa. FEBS Lett 125:208-212.
41. Yoda A and Hokin LE (1970) On the reversibility of binding of cardiotonic steroids to a partially purified (Na+K)-activated adenosinetriphosphatase from beef brain. Biochem Biophys Res Commun 40:880-886.